BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 28888355)

  • 1. The correlation of controlled attenuation parameter results with ultrasound-identified steatosis in real-world clinical practice.
    Yen YH; Chen JF; Wu CK; Lin MT; Chang KC; Tseng PL; Tsai MC; Lin JT; Hu TH
    J Formos Med Assoc; 2017 Nov; 116(11):852-861. PubMed ID: 28888355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound.
    Carvalhana S; Leitão J; Alves AC; Bourbon M; Cortez-Pinto H
    Liver Int; 2014 Jul; 34(6):e111-7. PubMed ID: 24034415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography.
    Myers RP; Pollett A; Kirsch R; Pomier-Layrargues G; Beaton M; Levstik M; Duarte-Rojo A; Wong D; Crotty P; Elkashab M
    Liver Int; 2012 Jul; 32(6):902-10. PubMed ID: 22435761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.
    de Lédinghen V; Vergniol J; Foucher J; Merrouche W; le Bail B
    Liver Int; 2012 Jul; 32(6):911-8. PubMed ID: 22672642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlled attenuation parameter for evaluating liver steatosis in chronic viral hepatitis.
    Ferraioli G; Tinelli C; Lissandrin R; Zicchetti M; Dal Bello B; Filice G; Filice C
    World J Gastroenterol; 2014 Jun; 20(21):6626-31. PubMed ID: 24914387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic performance of controlled attenuation parameter for predicting steatosis grade in chronic hepatitis B.
    Cardoso AC; Beaugrand M; de Ledinghen V; Douvin C; Poupon R; Trinchet JC; Ziol M; Bedossa P; Marcellin P
    Ann Hepatol; 2015; 14(6):826-36. PubMed ID: 26436354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic accuracy of controlled attenuation parameter measured by transient elastography for the non-invasive assessment of liver steatosis: a prospective study.
    Lupșor-Platon M; Feier D; Stefănescu H; Tamas A; Botan E; Sparchez Z; Maniu A; Badea R
    J Gastrointestin Liver Dis; 2015 Mar; 24(1):35-42. PubMed ID: 25822432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of hepatic steatosis index, controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B.
    Xu L; Lu W; Li P; Shen F; Mi YQ; Fan JG
    Dig Liver Dis; 2017 Aug; 49(8):910-917. PubMed ID: 28433586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population.
    Chon YE; Jung KS; Kim SU; Park JY; Park YN; Kim DY; Ahn SH; Chon CY; Lee HW; Park Y; Han KH
    Liver Int; 2014 Jan; 34(1):102-9. PubMed ID: 24028214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultrasound and FibroScan
    Salmi A; di Filippo L; Ferrari C; Frara S; Giustina A
    Endocrine; 2022 Nov; 78(2):262-269. PubMed ID: 35980569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled attenuation parameter for the detection of hepatic steatosis in patients with chronic hepatitis B.
    Chen J; Wu D; Wang M; Chen E; Bai L; Liu C; Liao J; Tang H
    Infect Dis (Lond); 2016 Sep; 48(9):670-5. PubMed ID: 27241724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of the controlled attenuation parameter for detecting liver steatosis in health checkup examinees.
    Kim JK; Lee KS; Choi JR; Chung HJ; Jung DH; Lee KA; Lee JI
    Gut Liver; 2015 May; 9(3):405-10. PubMed ID: 25717046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease.
    de Lédinghen V; Wong GL; Vergniol J; Chan HL; Hiriart JB; Chan AW; Chermak F; Choi PC; Foucher J; Chan CK; Merrouche W; Chim AM; Le Bail B; Wong VW
    J Gastroenterol Hepatol; 2016 Apr; 31(4):848-55. PubMed ID: 26514665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.
    Karlas T; Petroff D; Sasso M; Fan JG; Mi YQ; de Lédinghen V; Kumar M; Lupsor-Platon M; Han KH; Cardoso AC; Ferraioli G; Chan WK; Wong VW; Myers RP; Chayama K; Friedrich-Rust M; Beaugrand M; Shen F; Hiriart JB; Sarin SK; Badea R; Jung KS; Marcellin P; Filice C; Mahadeva S; Wong GL; Crotty P; Masaki K; Bojunga J; Bedossa P; Keim V; Wiegand J
    J Hepatol; 2017 May; 66(5):1022-1030. PubMed ID: 28039099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver Steatosis Assessed by Controlled Attenuation Parameter (CAP) Measured with the XL Probe of the FibroScan: A Pilot Study Assessing Diagnostic Accuracy.
    Sasso M; Audière S; Kemgang A; Gaouar F; Corpechot C; Chazouillères O; Fournier C; Golsztejn O; Prince S; Menu Y; Sandrin L; Miette V
    Ultrasound Med Biol; 2016 Jan; 42(1):92-103. PubMed ID: 26386476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical value of controlled attenuation parameter for the noninvasive assessment of liver steatosis.
    Ferraioli G; Tinelli C; De Silvestri A; Lissandrin R; Above E; Dellafiore C; Poma G; Di Gregorio M; Maiocchi L; Maserati R; Filice C
    Liver Int; 2016 Dec; 36(12):1860-1866. PubMed ID: 27439331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled attenuation parameter for steatosis grading in chronic hepatitis C compared with digital morphometric analysis of liver biopsy: impact of individual elastography measurement quality.
    Mendes LC; Ferreira PA; Miotto N; Zanaga L; Lazarini MS; Gonçales ESL; Pedro MN; Gonçales FL; Stucchi RSB; Vigani AG
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):959-966. PubMed ID: 29727388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled attenuation parameter for noninvasive assessment of hepatic steatosis using Fibroscan®: validation in chronic hepatitis B.
    Mi YQ; Shi QY; Xu L; Shi RF; Liu YG; Li P; Shen F; Lu W; Fan JG
    Dig Dis Sci; 2015 Jan; 60(1):243-51. PubMed ID: 25194851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does etiology affect performance?
    Kumar M; Rastogi A; Singh T; Behari C; Gupta E; Garg H; Kumar R; Bhatia V; Sarin SK
    J Gastroenterol Hepatol; 2013 Jul; 28(7):1194-201. PubMed ID: 23425053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A multi-center clinical study of a novel controlled attenuation parameter for assessment of fatty liver].
    Shen F; Zheng R; Mi Y; Shi J; Chen G; Chen J; Xu L; Pan Q; Xu L; Fan J
    Zhonghua Gan Zang Bing Za Zhi; 2014 Dec; 22(12):926-31. PubMed ID: 25654287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.